News
SPARTAN: Apalutamide delays second progression in nonmetastatic CRPC
BARCELONA – The androgen receptor inhibitor also appeared to show an overall survival benefit, but it did not reach significance in an interim...
News
Atezolizumab plus chemo gives slight PFS edge in mUC
BARCELONA – Adding the immune checkpoint inhibitor atezolizumab to platinum-based chemotherapy offered a modest PFS benefit over chemotherapy...
News
Ribociclib/fulvestrant boosts survival in advanced breast cancer
BARCELONA – The median overall survival for patients who received the CDK4/6 inhibitor plus fulvestrant has not been reached in the MONALEESA-3...
News
PARP inhibitor prolongs PFS in mCRPC
BARCELONA – The PROfound trial shows that targeted therapy can be effective against metastatic castration-resistant prostate cancer bearing DNA...
News
Immunotherapy duo extends survival in first line for advanced NSCLC
BARCELONA – Nivolumab and low-dose ipilimumab improved survival of patients with untreated advanced non–small cell lung cancer regardless of PD-L1...
News
Osimertinib improves survival in advanced NSCLC
BARCELONA – Osimertinib is the first TKI to show a survival advantage over another in advanced non–small cell lung cancer, FLAURA investigators...
News
Adjuvant radiotherapy no better than salvage post prostatectomy
BARCELONA – Men who underwent prostatectomy fared just as well with observation and salvage radiotherapy as with adjuvant radiotherapy.
News
Worse PFS when radiation is withheld in early-stage Hodgkin lymphoma
Patients negative for disease on PET scans after two chemotherapy cycles fared better with consolidation radiotherapy.
News
PBRM1 mutations not quite up to snuff as ccRCC biomarkers
Truncating mutations in PBRM1 are moderately linked to response to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma.
News
Many experimental drugs veer off course when targeting cancer
Ten anticancer drugs in development target proteins that are not essential for the survival or growth of cancer cells, investigators caution.
News
HER2-mutant NSCLC confers high brain metastases risk
Patients with HER2-mutated non–small cell lung cancer were more likely to develop brain metastases on therapy than patients with KRAS mutations....
News
Protons safe, effective for breast cancer control
Toxicity and disease control rates with proton-beam therapy to treat internal mammary nodes compared favorably with those of conventional...
News
Tandem transplants provide EFS edge in pediatric neuroblastoma
Patients randomized to tandem stem cell transplants after successful induction therapy had fewer events than patients assigned to single...
News
Molecular profiling a must in advanced NSCLC
Identification of targetable mutations and the advent of immune checkpoint inhibitors have improved outcomes for many patients.